Genetic Information Nondiscrimination in Health Insurance Act

Department of Defense Breast Cancer Research Program Dear Colleague letter to the Chairman of the Appropriations Defense Subcommittee in support of level funding of $175 million for the Department of Defense Breast Cancer Research Program. The Breast and Cervical Cancer Treatment Act H.R. 1070, Breast and Cervical Cancer Treatment Act of 1999, Section 1, “Optional Medicaid coverage of certain breast or cervical cancer patients.” S. 662, Breast and Cervical Cancer Treatment Act of 1999, Section 1, “Optional Medicaid coverage of certain breast or cervical cancer patients.” Breast Cancer and Environmental Research Act of 1999 H.R. 3433 / S. 2287, Breast Cancer and Environmental Research Act of 1999, Section 3, Amendments to Subpart 12 of part C of title IV of the Public Health Service Act that add research centers regarding environmental factors related to breast cancer. Medicare Cancer Clinical Trial Coverage Act of 1999 H.R. 1388, Medicare Cancer Clinical Trial Coverage Act of 1999, all provisions related to establishing “a demonstration project to study and provide coverage of routine patient care costs for Medicare beneficiaries with cancer who are enrolled in an approved clinical trial program” S. 784, Medicare Cancer Clinical Trial Coverage Act of 1999, all provisions related to establishing a demonstration project to study and provide coverage of routine patient care costs for Medicare beneficiaries with cancer who are enrolled in an approved clinical trial program Genetic Nondiscrimination Legislation H.R. 306, Genetic Information Nondiscrimination in Health Insurance Act of 1999, Section 2, Amendments to Employee Retirement Income Security Act of 1974; Subsection 714 Prohibition of health insurance discrimination on the basis of genetic information and Section 3 Amendments to the Public Health Service Act, Subsection 9814, Prohibition of discrimination by group health plans on the basis of genetic information. H.R. 2457 / S. 1322, Genetic Nondiscrimination in Health Insurance and Employment Act of 1999, Title I, all provisions relating to the prohibition of health insurance discrimination on the basis of predictive genetic information; Title II, all provisions relating to the prohibition of employment discrimination on the basis of predictive genetic information. Patients’ Bill of Rights: H.R. 2723, The Bipartisan Consensus Managed Care Act of 1999, Title I, Subtitle A – Grievance and Appeals, improving managed care through internal and external appeals processes; Subtitle B – Access to Care, Sec. 114 – providing for access to specialty care, Sec. 117 – providing for continuity of care, and Sec. 119 – providing for individuals participating in approved clinical trials. S. 6, Patients’ Bill of Rights Act of 1999, Subtitle A, all provisions relating to access to care specifically, Section 106, coverage for individuals participating in approved clinical trials and Section 105, continuity of care provisions. Also Subtitle F, Section 152, “standards relating to benefits for certain breast cancer treatment” and Subtitle D, grievance and appeals procedures.

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), President of the U.S., SENATE, Vice President of the U.S.

Telemedicine (HR 312, HR 3240, HR 4771, S 2505); Clinical Laboratory Improvement Amendments of 1999 (HR 528); genetic testing and confidentiality (HR 1507, HR 1941, HR 2404, HR 2455, HR 2470, S 573, S 578, S 881, HR 293, HR 306, HR 2457, S 543, S 1322, HR 2878, HR 4049, HR 4585); forensic pathology (HR 1915, HR 2340, S 1196, HR 2810, HR 3087, HR 3233, HR3375, S 1700, S 1981); bioterrorism; Pap smears (HR4330, HR 4571); Medicare issues pertaining to the laboratory; Allied Health Project Grants program (HR 4577); Medical liability reform (HR2242, HR 4577); graduate medical education (HR 1222, HR 1224, HR 1645, HR 1785, HR 2771, HR 4239, S 210, S541, S 1023, S 1024, S 1025, S 1631, S 2394); Patient access to care (HR 2723, HR 2824, HR 2926, HR 2990, HR 3146, S 6, S 326, HR 4577); Issues pertaining to microbiology, blood, diagnostic immunology, cytology, clinical chemistry, forensic pathology); telemedicine (HR 1344, HR 4771, S 2505); other diagnostic screening tests (HR 1285, HR 2930, S 1641, HR 1861, S 1044); rural health (HR 1344, HR 4677, S 1864, S 2735); patient safety (HR 3672, S 2038, S 2378, S 2738, S 2743); and genetics (HR 293, HR 306, HR 2457, HR 2878, S 543, S 1322).

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Clinical Laboratory Improvement Amendments of 1999 (HR 528); genetic testing and confidentiality (HR 1507, HR 1941, HR 2404, HR 2455, HR 2470, S 573, S 578, S 881, HR 293, HR 306, HR 2457, S 543, S 1322, HR 2878, HR 4049, HR 4585); forensic pathology (HR 1915, HR 2340, S 1196, HR 2810, HR 3087, HR 3233, HR3375, S 1700, S 1981); bioterrorism; Pap smears (HR4330, HR 4571); Issues pertaining to microbiology, blood, diagnostic immunology, cytology, clinical chemistry, forensic pathology); and other diagnostic screening tests (HR 1285, HR 2930, S 1641, HR 1861, S 1044).

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE